Medline Inc. MDLN
- Market cap
- $45.5B
- P/E
- —
Follow MDLN
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | 34.89 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | — | 45.50 |
High Price
|
|||
| — | — | — | — | — | — | — | — | 43,000 | 45,000 |
Employees
|
|||
| — | — | — | — | — | — | — | 0 | 1 | 1 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | 23,231 | 25,507 | 28,432 |
Revenue
|
|||
| — | — | — | — | — | — | — | 25.33% | 27.35% | 26.44% |
Gross Margin
|
|||
| — | — | — | — | — | — | — | 264 | 1,246 | 1,248 |
EBT
|
|||
| — | — | — | — | — | — | — | 1.14% | 4.88% | 4.39% |
EBT Margin
|
|||
| — | — | — | — | — | — | — | 234 | 1,200 | 1,157 |
Net Income
|
|||
| — | — | — | — | — | — | — | 1,121 | 1,059 | 1,070 |
Depreciation
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 35.10 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | — | 1.43 |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 2.15 |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | (0.55) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 1.60 |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 23.81 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | — | 810 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 1.76 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | 4.66 | 4.66 | 13.20 |
EV/FCF
|
|||
| — | — | — | — | — | — | — | 1,685 | 1,769 | 1,744 |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | (275) | (354) | (447) |
Capex
|
|||
| — | — | — | — | — | — | — | 1,410 | 1,415 | 1,297 |
FCF
|
|||
| — | — | — | — | — | — | — | — | 5,832 | 8,189 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | 16,494 | 12,561 |
Total Debt
|
|||
| — | — | — | — | — | — | — | — | 16,295 | 10,622 |
Net Debt
|
|||
| — | — | — | — | — | — | — | 0 | 16,158 | 19,286 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | 0.00% | 6.67% | 3.11% |
ROA
|
|||
| — | — | — | — | — | — | — | 0.00% | 4.13% | 4.62% |
ROIC
|
|||
| — | — | — | — | — | — | — | 0.00% | 0.00% | 6.54% |
ROE
|
|||
Medline Inc. peers in Medical Instruments & Supplies
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| BDX Becton, Dickinson and Company | $48.8B | 55.4× | Compare |
| RMD ResMed Inc. | $31.9B | 21.3× | Compare |
| ALC Alcon | $30.9B | 49.2× | Compare |
| WST West Pharmaceutical Services, Inc. | $26.3B | 47.1× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| SOLV Solventum Corporation | $15.1B | 10.9× | Compare |
| ISRG Intuitive Surgical, Inc. | $140.7B | 45.8× | Compare |
| BAX Baxter International Inc. | $12.2B | 0.0× | Compare |
| RGEN Repligen Corporation | $10.8B | 253× | Compare |
Medline Inc. (MDLN) key facts
- Medline Inc. (MDLN) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
- Medline Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.4 billion, up 11.5% from fiscal 2024.
- Net income was $1.2 billion, or $1.43 per share (basic), a net margin of 4.08%.
- As of September 25, 2026, MDLN traded at $34.70, a market capitalization of $45.5 billion.
- Return on equity was 6.54% and debt-to-equity 0.66.
Medline Inc. (MDLN) Latest News
19 Sep
Medline (MDLN) shares fell 22% and could trade below fair value. A 22% share price drop directly affects near-term market sentiment and valuation perceptions for MDLN.
4 Sep
Artisan sold its Medline Inc. (MDLN) holdings because cost pressures delayed the company's profit recovery. Cost pressures delaying profit recovery triggered a notable investor sale that can affect short-term market sentiment and company trajectory.
12 Aug
Medline Inc. (MDLN) released its Q2 2026 earnings call transcript, covering financial results, operational updates, and forward outlook. Earnings call details typically provide moderate updates on performance and guidance that influence near-term sentiment without guaranteeing major strategic shifts.
5 Aug
Medline Inc (MDLN) posted strong Q2 2026 growth during its earnings call amid ongoing strategic initiatives. Strong growth and strategic moves signal major positive shifts for Medline Inc future performance.
Medline Inc. (MDLN) stock falls sharply after fire at Tracy facility drives 58% net income drop. Facility fire triggered 58% net income decline with direct effects on operations and financial results.
Medline Inc. (MDLN) Q2 earnings call highlighted financial performance, revenue figures, and operational updates. Q2 earnings details may shift short-term investor sentiment and influence operational outlook.
Medline (MDLN) Q2 earnings include key metrics analyzed for performance details. Q2 earnings metrics analysis influences short-term market views on financial results.
Medline Inc. (MDLN) reported financial results for the second quarter and first six months of 2026. Quarterly earnings updates supply performance data that can shift near-term investor sentiment and valuation.
22 Jul
Medline (MDLN) COO exits while company secures new health deal, shifting focus to valuation. COO exit combined with new deal may affect operations and sentiment but not fundamentally alter company trajectory.
4 Jul
Jim Cramer names Medline Inc. (MDLN) the best IPO of the year. Jim Cramer's positive endorsement can boost short-term investor sentiment and visibility for MDLN stock.
6 Jun
FDA warning questions Medline Inc.'s quality systems and threatens its earnings narrative. FDA warning poses direct challenge to Medline quality controls and earnings projections.
29 May
Medline expands Prime Vendor model outside the United States. International rollout of Prime Vendor model marks major strategic growth move for Medline.
7 May
Medline Inc. (MDLN) Q1 earnings reveal key metrics compared to Wall Street estimates. Q1 earnings metrics versus estimates directly sway investor sentiment and stock trajectory.
6 May
Medline Inc. (MDLN) released Q1 earnings call highlights detailing financial results, operational updates, and future outlook. Q1 earnings call highlights cover financial metrics, guidance, and strategy, poised to significantly shape investor sentiment and company trajectory.
Medline (MDLN) launches AI-powered Mpower platform to enhance healthcare supply chain resiliency. AI-powered Mpower platform launch is a major strategic move improving supply chain efficiency and competitive positioning in healthcare.
Medline Inc. (MDLN) reported first quarter 2026 results. Quarterly earnings releases significantly impact financial performance metrics and investor sentiment toward future market trajectory.
4 May
Medline launches Mpower™, a digital control tower to predict, respond, and resolve supply chain risks. Mpower™ launch delivers a major strategic tool for supply chain optimization, enhancing Medline's efficiency and competitive positioning.
28 Apr
Symbotic and Medline Inc. (MDLN) announce deal to test Symbotic's AI-powered warehouse automation platform in Medline's healthcare distribution operations, marking a key push into healthcare sector efficiency. Partnership with Symbotic deploys AI warehouse tech in Medline's core healthcare distribution, likely enhancing operational efficiency and competitive edge significantly.
26 Apr
Medline Inc. (MDLN) partners with Symbotic to deploy AI-powered warehouse automation systems, aiming to boost efficiency, throughput, and scalability across its distribution network. AI warehouse automation partnership drives major operational efficiencies, cost savings, and competitive edge in healthcare supply chain.
16 Apr
Medline Inc. announces the first-in-healthcare AI robotics partnership with Symbotic to revolutionize supply chain operations. Pioneering AI robotics partnership introduces transformative automation to healthcare supply chains, significantly boosting efficiency and competitive positioning.
14 Apr
Medline Inc. (MDLN) received an FDA warning letter citing quality control lapses in manufacturing angiographic syringes, including inadequate process validation, contamination risks, and failure to investigate deviations. FDA warning letters for quality issues in medical devices often lead to production halts, costly remediation, intensified scrutiny, and negative investor sentiment, significantly impacting future operations and market performance.
10 Apr
Medline Inc. (MDLN) launches Pick Pack Pro fulfillment technology in New York to enhance distribution efficiency. Launching advanced fulfillment technology drives operational improvements and strengthens competitive positioning in logistics.
9 Apr
The FDA issued a warning letter to Medline Inc. for manufacturing failures in angiographic syringes, citing issues like inadequate process controls, contamination risks, and failure to investigate deviations. FDA warning letters on manufacturing can disrupt specific product lines, trigger recalls, and impose remediation costs without fundamentally altering overall operations.
6 Apr
Medline Inc. (MDLN) launches Pick Pack Pro™, a custom product fulfillment technology designed to streamline operations and enhance efficiency for customers. Pick Pack Pro™ launch is a major strategic product innovation in fulfillment technology that could significantly enhance Medline's operational efficiency and competitive positioning.
5 Apr
Medline Inc. receives supply chain awards and reports safety gains, positively informing investor views on company risks. Supply chain awards and safety gains moderately enhance investor risk perceptions and market sentiment.
2 Apr
Medline Inc. (MDLN) signs new prime vendor agreement with CarDon, enhancing its distribution network in healthcare supplies. New prime vendor agreement with CarDon boosts Medline's revenue potential and competitive positioning in healthcare distribution.
31 Mar
March megadeals anchored global equity capital markets in Q1 2026 despite Middle East war uncertainties, with Medline Inc. (MDLN) featured prominently. Megadeals position MDLN for significant strategic growth and investor interest amid market volatility.
24 Mar
Brown Advisory's Mid-Cap Growth Strategy invests in Medline Inc. (MDLN) ahead of its IPO, signaling confidence in the medical supplies distributor's growth prospects. Prominent fund's pre-IPO investment boosts investor confidence and could significantly enhance Medline's valuation and market debut.
14 Mar
Medline Inc. (MDLN) plans to expand its distribution centers to enhance supply chain efficiency and support growing demand. Expanding distribution centers constitutes a major strategic investment in logistics that will significantly improve operational scalability and market competitiveness.
11 Mar
Medline Inc. (MDLN) breaks ground on a 1.2 million sq. ft. distribution center in Midlothian, Texas, underscoring its ongoing growth and expansion efforts. Construction of a massive 1.2 million sq. ft. distribution center signals major operational expansion, boosting capacity and supporting future growth trajectory.